Exciting New Prostate Cancer Treatment Options – 2016/17

Researchers at the 2015 Genitourinary Cancers Symposium reported no new good findings for medical treatments. Instead, the prognoses of some treatments such as abiraterone acetate plus prednisone only allowed 13% of patients with prostate cancer that had already metastasized to reduce their PSA levels to less than or equal to 0.2 ng/ml within one year.

In another trial of men with prostate cancer and bone metastasis, cabozantinib was tested against prednisone. There was no difference between the two groups. In fact, 42% of those receiving the cabozantinib had a 30% reduction or more of bone lesions compared to 3% in the …read more